NASDAQ Framework: ACADIA Pharmaceuticals Inc.
Biopharmaceuticals, CNS disorders, innovative treatments 1.
1: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. View Source
ACADIA Pharmaceuticals Inc., headquartered in San Diego, California, is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and DAYBUE, a novel synthetic analog for the treatment of Rett Syndrome. Additionally, ACADIA is engaged in various stages of clinical development for other CNS-related treatments, including schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and Fragile X syndrome 2.
2: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. View Source
UNKNOWN
The provided facts do not contain specific information about whether ACADIA Pharmaceuticals Inc. is still led by its founders or if the founders are heavily involved in the company's current operations.
The provided facts do not contain specific information about whether ACADIA Pharmaceuticals Inc. is still led by its founders or if the founders are heavily involved in the company's current operations.
LOW RISK
ACADIA Pharmaceuticals Inc. demonstrates strong financial health, as evidenced by its impressive revenue growth rate of 73.75% as of March 31, 2024, and a net margin of 8.04%, which signifies efficient cost management 34. The company also boasts a remarkable Return on Equity (ROE) of 3.7% and a Return on Assets (ROA) of 2.06%, indicating efficient use of equity capital and assets for optimal returns 56. Additionally, ACADIA Pharmaceuticals maintains a prudent financial strategy with a below-average debt-to-equity ratio of 0.13, reflecting balanced debt management 7. These financial metrics collectively suggest that ACADIA Pharmaceuticals Inc. is in a stable and low-risk financial position.
ACADIA Pharmaceuticals Inc. demonstrates strong financial health, as evidenced by its impressive revenue growth rate of 73.75% as of March 31, 2024, and a net margin of 8.04%, which signifies efficient cost management 34. The company also boasts a remarkable Return on Equity (ROE) of 3.7% and a Return on Assets (ROA) of 2.06%, indicating efficient use of equity capital and assets for optimal returns 56. Additionally, ACADIA Pharmaceuticals maintains a prudent financial strategy with a below-average debt-to-equity ratio of 0.13, reflecting balanced debt management 7. These financial metrics collectively suggest that ACADIA Pharmaceuticals Inc. is in a stable and low-risk financial position.
3: Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 73.75%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. View Source4: Net Margin: ACADIA Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 8.04%. This signifies efficient cost management and strong financial health. View Source5: Return on Equity (ROE): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.7%, the company showcases efficient use of equity capital and strong financial health. View Source6: Return on Assets (ROA): ACADIA Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.06% ROA, the company effectively utilizes its assets for optimal returns. View Source7: Debt Management: With a below-average debt-to-equity ratio of 0.13, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management. View Source
8: Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med Business Wire Jul 18, 2024 1:04pm Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting Business Wire Jun 18, 2024 1:04pm Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire May 17, 2024 8:05pm Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome Business Wire May 15, 2024 1:05pm Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Business Wire May 9, 2024 8:58pm Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview Business Wire May 8, 2024 8:05pm Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship Business Wire Apr 29, 2024 8:16pm Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 Business Wire Apr 24, 2024 8:05pm Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada Business Wire Apr 22, 2024 1:04pm Acadia Pharma's stock falls 15% after failed drug trial MarketWatch Mar 12, 2024 12:17am Acadia Pharmaceuticals stock rockets 30% following expanded drug rights MarketWatch Jul 13, 2023 8:41pm View Source9: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. View Source
ACADIA Pharmaceuticals Inc. has a robust product roadmap and expansion strategy for 2024 through 2026, focusing on the development and commercialization of innovative treatments for CNS disorders and rare diseases. The company is advancing several key programs, including the Phase III ADVANCE-2 study of Pimavanserin for the treatment of negative symptoms of schizophrenia, ACP-101 for hyperphagia in Prader-Willi syndrome, ACP-204 for Alzheimer's disease psychosis, and ACP-2591 for Rett syndrome and Fragile X syndrome 10. Additionally, ACADIA is leveraging its license agreements with Neuren Pharmaceuticals Limited and Stoke Therapeutics, Inc. to develop and commercialize novel RNA-based medicines and other treatments for severe and rare genetic neurodevelopmental diseases of the CNS 11. This strategic focus positions ACADIA to address significant unmet medical needs and drive long-term growth.
10: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. View Source11: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. View Source